Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | PLAU | P00749 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27495132 | 0.96 | MEN1 (0.54) | MEN1KMT2AL3MBTL1KDM4EPLAU | |
| SCHEMBL4016085 | 0.96 | MEN1 (0.57) | MEN1KMT2AL3MBTL1KDM4EPLAU | |
| SCHEMBL305422 | 0.83 | LMNA (0.56) | KMT2AL3MBTL1LMNATDP1 | |
| SCHEMBL4016323 | 0.83 | KMT2A (0.51) | MEN1KMT2AL3MBTL1PLAUTSHR | |
| SCHEMBL7503901 | 0.82 | PTGS2 (0.64) | MEN1KMT2AL3MBTL1KDM4EPLAU | |
| SCHEMBL10497942 | 0.81 | PKM (0.67) | HTTPTGS2PKM | |
| SCHEMBL18007557 | 0.81 | LMNA (0.60) | MEN1KMT2AL3MBTL1KDM4EPLAU | |
| SCHEMBL1726389 | 0.81 | MEN1 (0.61) | MEN1KMT2AL3MBTL1KDM4EPLAU | |
| SCHEMBL28564051 | 0.81 | NFE2L2 (0.51) | LMNATDP1PKM | |
| SCHEMBL132263 | 0.81 | MEN1 (0.57) | MEN1KMT2AL3MBTL1KDM4EPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| CN-101553481-A | Substituted sulfonamide derivatives | GRUENENTHAL GMBH (DE) | 2009-10-07 | — | — | CN | disclosed |
| EP-1085540-B1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | SHOWA DENKO KK (JP) | 2009-07-01 | — | — | EP | disclosed |
| EP-1158551-B1 | SOLID ELECTROLYTIC CAPACITOR AND ITS PRODUCTION METHOD | SHOWA DENKO KK (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1811532-A2 | Solid electrolytic capacitor and method for producing the same | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1190426-B1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PRODUCING THE SAME | SHOWA DENKO KK (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| EP-1085540-A1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | Showa Denko K K (JP) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000060620-A1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PRODUCING THE SAME | SHOWA DENKO K. K. (JP) | 2000-10-12 | — | — | WO | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | PTGS2 182/4885MEN1 4354/4885KMT2A 1686/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | PTGS2 182/4885MEN1 4354/4885KMT2A 1686/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | PTGS2 182/4885MEN1 4354/4885KMT2A 1686/4885 |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | PTGS2 666/4885MEN1 998/4885KMT2A 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.